Related Experiment Video

Updated: Jun 7, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

EGFR-activating mutations are not present in breast tumors of Japanese patients

Hidetaka Uramoto1, Hidehiko Shimokawa, Yoshika Nagata

  • 1Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, Japan. hidetaka@med.uoeh-u.ac.jp

Anticancer Research
|November 2, 2010
PubMed
Abstract

Insights

EGFR mutations were not found in Japanese breast cancer patients. Therefore, EGFR tyrosine kinase inhibitors are unlikely to be effective for this patient group.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Recurrent breast cancer remains a significant cause of mortality despite treatment advancements.
  • The epidermal growth factor receptor (EGFR) family is implicated in breast cancer development.
  • Limited data exists on EGFR mutations and EGFR tyrosine kinase inhibitor (TKI) efficacy in Japanese breast cancer patients.

Purpose of the Study:

  • To investigate the frequency of EGFR-activating mutations in Japanese breast cancer patients.
  • To assess the potential role of EGFR TKIs in treating breast cancer in this population.

Main Methods:

  • Tumor specimens were obtained from 84 surgically treated breast cancer patients.
  • Polymerase chain reaction (PCR) was employed to detect EGFR mutations in exons 19 and 21.

Main Results:

  • No activating mutations within the EGFR tyrosine kinase domain were detected in any of the analyzed tumors.
  • The study found a complete absence of EGFR-activating mutations in the examined Japanese breast cancer cohort.

Conclusions:

  • EGFR-activating mutations are not present in the studied Japanese breast cancer population.
  • Consequently, EGFR TKIs are unlikely to offer therapeutic benefits for Japanese breast cancer patients, contrasting with their use in lung cancer.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...